Hydrochloric Acid → 4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]aniline

HRID 1095407Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1095407
[CH3:1][C@H:2]1[CH2:7][O:6][CH2:5][CH2:4][N:3]1[C:8]1[CH:13]=[C:12]([CH2:14][S:15]([CH3:18])(=[O:17])=[O:16])[N:11]=[C:10]([C:19]2[CH:24]=[CH:23][C:22]([NH:25]C(=O)OC(C)(C)C)=[CH:21][CH:20]=2)[N:9]=1.Cl>CO.O1CCOCC1>[CH3:1][C@H:2]1[CH2:7][O:6][CH2:5][CH2:4][N:3]1[C:8]1[CH:13]=[C:12]([CH2:14][S:15]([CH3:18])(=[O:17])=[O:16])[N:11]=[C:10]([C:19]2[CH:24]=[CH:23][C:22]([NH2:25])=[CH:21][CH:20]=2)[N:9]=1

Komponenten

5

Edukt 2

HCID 313Hydrochloric AcidHCID 59508397tert-butyl N-[4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]phenyl]carbamate

Produkt 1

HCID 595083934-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]aniline

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 887MethanolLösungsmittelHCID 312751,4-DioxaneLösungsmittel

Versuchsvorschrift

tert-Butyl N-[4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]phenyl]carbamate (1.09 g, 2.35 mmol) was dissolved in methanol (5 mL) and 4M hydrogenchloride in dioxane (5 mL) was added. The solution was stirred at room temperature overnight, then the mixture evaporated to a dark brown oil and dissolved in ethyl acetate (10 mL). Water (5 mL) was added followed by the addition of sodium bicarbonate solution until neutral pH was achieved (˜2 mL). The phases were separated and the organic phase washed with water (10 mL). The organic layer was dried over magnesium sulphate and evaporated to a pale yellow foam (805 mg).

Aufarbeitung

  1. customthe mixture evaporated to a dark brown oil
  2. dissolutiondissolved in ethyl acetate (10 mL)
  3. additionWater (5 mL) was added
  4. additionfollowed by the addition of sodium bicarbonate solution until neutral pH
  5. customThe phases were separated
  6. washthe organic phase washed with water (10 mL)
  7. dry with materialThe organic layer was dried over magnesium sulphate
  8. customevaporated to a pale yellow foam (805 mg)

Quellen und Nachweise

ORD-Eintrag
ord-ed4c7e6fb64549d6881af51a6ce0dec1
Quelldatensatz
uspto-grants-2012_03
Patentnummer
US08138183B2

Notizen zur Reaktion

Wird geladen…